Clinical Trials

Home > About >

Clinical Trials

We strive to offer the latest knowledge and cutting-edge medical technology to our patients for treatment of their conditions. We are actively participating in several FDA sanctioned clinical trials as well as numerous IRB approved clinical studies. In patients with complex ocular problems, if indicated, clinical trial may offer our patients the chance to receive treatments that are not available elsewhere.

Clinical trials are not for everyone. Patient selection and visits are rigorous to ensure efficacy for the participants. Patients are extremely carefully monitored to ensure the safety. The best interest of patients is always our priority and patients will always have direct communications with our study staff.

If you are interested in any of these trials,
please contact our Palisades Park office at 201-461-0021.

Palisades Park Office

IONTOPHORETIC DEXAMETHASONE PHOSPHATE OPTHALMIC SOLUTION FOR ANTERIOR SEGMENT UVEITIS

The purpose of this study is to evaluate the safety and efficacy of ocular iontophoresis with dexamethasone phosphate ophthalmic solution EGP-437 using the EyeGate® II Drug Delivery System (EGDS) compared to prednisolone acetate ophthalmic suspension (1%) in patients with non-infectious anterior segment uveitis.

Requirements: Male or female, age 12 to 85 years with a diagnosis of non-infectious anterior segment uveitis defined as an anterior chamber cell count of greater than or equal to 11 cells
Sponsor: EyeGate Pharmaceuticals, Inc.
Status: Closed for Enrolling

Humira for uveitis

Visual I (active), Visual II (inactive) and VISUAL III (open-label)
The purpose of this studies is to compare the safety and efficacy of Adalimumab vs. Placebo in subjects with active or inactive uveitis.

Requirements: Subject is at least 18 years of age and is diagnosed with non-infectious intermediate-, posterior-, or pan-uveitis.

Sponsor: AbbVie
Status: Enrolling

Tocilizumab for Uveitis

The purpose of this study is to evaluate the safety, tolerability, and bioactivity of two doses of Tocilizumab (4mg/kg and 8mg/kg), administered monthly, in patients with non-infectious intermediate, posterior, or panuveitis.

Requirements: 18 years of age and older, have diagnosis of active non-infectious uveitis, defined as having at least 1+ Vitreous Haze (SUN scale) in study eye.

Sponsor: John Hopkins University
Status: Enrolling

Newark Office

Eye Institute of New Jersey

The purpose of this study is to see the correlation between amount of uptake on gallium scan and biopsy results at University of Medicine and Dentistry of New Jersey-New Jersey Medical School.

Status: Closed for enrollment

Voclosporin for uveitis

The primary objective of this study is to assess the safety and efficacy of voclosporin as therapy in subjects with active noninfectious uveitis involving the intermediate and/or posterior segments of the eye (i.e., anterior + intermediate-, intermediate-, posterior- or pan-uveitis).

Requirements: 18 years or older with active noninfectious uveitis involving the intermediate and/or posterior segment (i.e., anterior + intermediate-, intermediate-, posterior- or pan-uveitis) in at least one eye as evidenced by a vitreous haze grade of at least 2+ at the baseline visit. Subjects who also have anterior segment involvement need not be excluded if otherwise qualified.

Sponsor: Lux Biosciences Inc.
Status: Closed for enrollment

Sirolimus Opthalmic Solution for Active Uveitis

Sakura Study: The purpose of this study is to find out about the safety and effectiveness of the study drug, sirolimus, in patients with uveitis and to utilize the potential effectiveness of sirolimus, and yet to avoid the potential complications of systemic use of the drug. In this study, the investigators will administer sirolimus either around (subconjunctival injection) or inside the eye (intravitreal injection). Local administration of sirolimus to the eye is not expected to have effects on the rest of the body. Therefore, it may offer a safer way than the current methods used to control the inflammation caused by non-infectious uveitis.

Requirements: Subject must be 18 years or older and have diagnosis of uveitis determined by the Investigator to be non infectious.

Sponsor: Santen, Inc.
Status: Enrolling

Teaneck Office

Systane Versus Optive for Severe Dry Eye

The purpose of this study is to compare two artificial tear products efficacy in moderate to severe dry eye.

Requirements: Subject must be 18 years of age and older with moderate to severe dry eye.

Sponsor: Alcon Research
Status: Closed for enrollment

AIN457 for uveitis

This study will test the efficacy and safety of AIN457 for patients with active uveitis that requires systemic immunosuppression.

Requirements: Subject must be between 18 and 75years of age and have Intermediate uveitis, posterior uveitis, or panuveitis sufficiently severe that systemic immunosuppression is indicated.

Sponsor: Novartis
Status: Closed for Enrollment